We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this. Whatever happens, though ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...
MoneyWeek on MSN12d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback